| Name | Title | Contact Details |
|---|
Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. Catalent develops. With our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. Catalent delivers. As the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, we provide integrated solutions to take your product from design, to clinical trial, to plant, and to pharmacy.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
With a reputation as an innovative provider of quality care, Southwell is a growing, not-for-profit health system serving 12 counties in South Central Georgia. Southwell offers more than 135 physicians with expertise in over 30 specialties. Southwell provides a wide-range of care, including signature services in surgery, oncology, cardiovascular care, women`s health, neurodiagnostics, geriatric psychiatric care, radiology and more. The Main Campus is Tift Regional Medical Center, a 181-bed regional referral hospital located in Tifton. Our Tifton West Campus houses various diagnostic services and the region`s largest multi-specialty clinic. Our Cook County campus is anchored by Southwell Medical, an acute care facility which includes state-of-the-art surgical services and a 12-bed geriatric psychiatric unit. The Cook campus also includes Southwell Health and Rehabilitation, a 95-bed skilled rehabilitation facility.
Matheny Medical and Educational Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Peapack, NJ. To find more information about Matheny Medical and Educational Center, please visit www.matheny.org
Neich Medical Co. is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.